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Letters to the
Editor
Radial versus right internal thoracic
artery for myocardial
revascularization
To the Editor:
Buxton and colleagues1 recently reported
interim results of a randomized controlled
trial (RCT) of alternative conduits for the
second graft in patients having coronary
artery bypass grafting. They concluded that
“the 5-year interim results do not support
the hypothesis that the radial artery (RA)
has superior patency to or is associated
with fewer clinical events than free right
internal thoracic (RITA) or saphenous vein
(SV) grafts.” We argue below that this con-
clusion is misleading.
First, the paper does not present 5-year
results. The last patient was recruited 2
months before the paper was received. The
median duration of follow-up is not stated
but from the Kaplan Meier graphs appears
to be about 2.5 years. Plotting survival
graphs when few patients remain at risk
disguises the imprecision of the estimates
at these time points.2
Second, the paper represents an interim
analysis but does not state (1) whether the
analysis was specified in the protocol, (2)
the criteria for acting on the results of the
interim analysis, or (3) whether any action
has subsequently been taken. It is not clear
whether the trial continues to recruit.
Interim analyses of treatment effects
aim to prevent participants and other pa-
tients receiving a treatment known to be
inferior.3-5 They should be specified in the
protocol, together with proposed actions
(ie, stopping rules).3,4 Interim results
should be disclosed only to the Data and
Safety Monitoring Board (DSMB), not to
the investigators.3,5 If the DSMB recom-
mends specific actions (eg, stopping the
trial early), the investigators have respon-
sibility for definitive analyses. Statistical
criteria for actions are usually set at a more
stringent level than for final analyses (eg, P
 .001).3,5 If the DSMB concludes no ac-
tion is required, disclosing interim results
can prejudice successful completion of the
trial.3
Third, the authors report a target sample
size based on higher risks of events than
were observed. For patency, the sample
size is also much smaller than the target.
Consequently, the analyses of patency have
little power to detect the target difference.
For example, with about 35 patients in each
group (ie, for the comparison of RA versus
RITA), the analysis had only about 28%
power to detect the stated target difference.
The analyses of survival free from cardiac-
related events also have less power than
suggested because only half the partici-
pants had reached about 2.5 years of fol-
low-up.
We believe the target sample size is
optimistic, even for the planned 10-year
analysis. A relative risk smaller than the
0.33 implied by the predicted event risks is
likely to be clinically worthwhile. Table 1
shows the power and sample sizes for dif-
ferent baseline event risks (bracketing
those chosen by the authors), assuming a
constant relative risk of 0.67 (our estimate
of the minimum effect likely to change
practice). For the tabulated baseline event
rates, the rates for the comparison group
would be 8% and 11%, respectively (abso-
lute differences of 4% and 5%).
Fourth, the results may also be seriously
biased. The authors excluded 40 random-
ized patients from the graft patency study
because of the “poor quality of the ran-
domly assigned conduit (eg, damaged dur-
ing removal)” or because “the appropriate
coronary artery was not grafted.” The in-
vestigators should have kept these patients
in the study as damage to the conduit or
inappropriate grafting are likely to affect
the overall outcome for a patient and may
be related to the type of graft. The decision
to exclude a patient could not have been
blinded to the randomly assigned conduit.
The distribution of excluded patients by
group is not reported.
The conclusion is stated as a refutation
of the hypothesis that RA grafts have su-
perior patency than RITA or SV grafts.
This conclusion is misleading because the
analyses had very little chance of detecting
the target differences even if they truly
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exist. The publication is likely to influence
the attitudes of cardiac surgeons and may
jeopardize future better-designed and better-
executed RCTs of an important question.
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Reply to the Editor:
We thank Professor Angelini and col-
leagues for raising several important issues
in relation to our trial.1 However, we do not
agree that the conclusion of our article is
misleading, and we believe that the issues
raised in their letter can be simply and
easily addressed.
The article presents the results 5 years
after trial inception. We make that perfectly
clear in the text and display the mean du-
ration of follow-up in a graphic format with
the Kaplan-Meier graphs. Pocock’s con-
cerns about the imprecision of estimates as
displayed by such graphs in the presence of
few events relates to the risk of conveying
a visual impression of a difference where
none exists. This is of moot concern in a
graphic display of actual lack of differ-
ence.2
This interim analysis was not planned;
it represented a response of the group of
cardiac surgeons, cardiologists, intensiv-
ists, and cardiac anesthesiologists involved
in the trial to the aggressively promoted
view that radial artery conduits are “best,”
a view also strongly espoused by Professor
Angelini and colleagues3 on the basis of
nonrandomized data. A decision to under-
take an interim 5-year graft patency analy-
sis was made to ensure that, with the best of
the data available so far, the design of the
trial did not expose our patients to “unsafe
surgical practice.” No criteria were for-
mally set for “stopping” the trial. The data
were presented to the physicians involved
in the trial and, following discussion, a
unanimous decision was made to continue
the study. The enrollment of 556 patients is
now complete.
We agree about the importance of in-
terim analyses for the purpose of patient
safety. However, the methodology sug-
gested by the correspondents is typically
that of large multicenter drug company-
sponsored trials, where major financial
conflicts of interest exist. In such studies,
the need for an impartial Data and Safety
Monitoring Board (DSMB) is obvious. The
need for a DSMB in single-center studies,
where the patients are known to all physi-
cians involved and are regularly seen in
outpatient clinics, is empirically unproven.
Furthermore, the statistical criteria for ac-
tion cannot, in our opinion, be sensibly
taken as an absolute but must be seen
within a Bayesian analysis of the pretest
probability of a particular outcome being
correct.4 We note that no gold standard
exists to empirically validate the sensitivity
and specificity of current statistical criteria
for trial cessation. The probabilities of a
difference between groups1 approximate
unity, a far cry from the extreme statistical
“stopping” values as suggested by O’Brien
and Fleming and the Peto-Haybittle rule to
avoid a type 1 error.5,6
Our study might be underpowered.
However, the number of events seen in this
interim group of patients may not be rep-
resentative of the whole population. Fur-
thermore, we anticipate that most of the
outcome events will be seen in the latter
half of the trial, and therefore, the estima-
tion of sample size based on information
from the interim analysis is inappropriate.
We invite caution and consider that more
interim information is needed before a re-
calculation of sample size is necessary. We
agree that our report contains data with
limited statistical power. As this was a
safety analysis aimed at excluding only a
major difference between the 2 groups, we
believe our observations are important to
the continued conduct of this and other
studies, hence the publication.
All 438 patients1 were included in the
clinical outcomes analyses, which were
based on an “intention-to-treat.” Forty-two
patients were excluded from the graft pa-
tency study: 21 were radial artery trial
grafts and 21 were controls (16 right inter-
nal thoracic artery and 5 saphenous vein
grafts). Two patients of the 42 refused an-
giography and 23 were excluded because
of graft disease. In 2 patients the wrong
conduit was used and in the remaining 15
patients, the correct grafts were used, al-
TABLE 1. Power* of comparisons based on different sample sizes and cumulative event rates
Cumulative
event rate
at 10 years
in RITA
group (%)
Number of patients per group
200 300 400 500 600 700 800 900 1000 1200 1400 1600 1800 2000
12 17.7 24.2 30.7 36.9 42.9 48.6 53.8 58.8 63.3 71.2 77.7 82.9 87.0 90.2
16 23.9 33.3 42.3 50.6 58.0 64.6 70.4 75.4 79.7 86.4 91.0 94.2 96.3 97.7
RITA, Right internal thoracic artery.
*Power estimates assume: (1) recruitment over 6 years, (2) maximum duration of follow-up of 10 years, (3) 5% significance level (2-tailed), (4) analysis by
log rank test.
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